| Product Code: ETC8834537 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Ravi Bhandari | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The angina market in the Philippines is expanding due to rising cardiovascular disease prevalence, driven by sedentary lifestyles, poor diet, and stress. Increasing access to diagnostics and awareness campaigns are promoting early detection. Treatments include beta-blockers, calcium channel blockers, nitrates, and lifestyle modification. Urban hospitals provide comprehensive cardiac care, but rural health systems still face challenges in managing chronic conditions effectively.
The angina market in the Philippines is growing in response to rising cardiovascular disease prevalence, driven by urbanization and lifestyle changes. Increased screening and diagnostic facilities improve detection, while the availability of effective pharmacological and interventional treatments supports market expansion. Patient education and cardiac rehabilitation programs further enhance disease management.
Angiogenesis inhibitor markets face significant challenges related to the high cost of biologic therapies, which restricts patient access in a price-sensitive healthcare market. Regulatory approval processes can be lengthy, delaying entry of innovative drugs. The need for specialized administration and monitoring limits these treatments to advanced care centers.
The angina market in the Philippines remains robust due to the high prevalence of cardiovascular diseases linked to lifestyle changes and urbanization. Investments in advanced pharmaceuticals, diagnostic tools, and cardiac rehabilitation programs can address growing patient needs. Government health initiatives focused on cardiovascular health offer a supportive environment for expanding market presence.
Angina is addressed within the national cardiovascular disease prevention and management programs. The government promotes access to diagnostic services, pharmacological treatment, and lifestyle modification support through primary healthcare facilities. Universal Health Care (UHC) policies facilitate coverage for angina management under PhilHealth.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines Angina Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines Angina Market Revenues & Volume, 2021 & 2031F |
3.3 Philippines Angina Market - Industry Life Cycle |
3.4 Philippines Angina Market - Porter's Five Forces |
3.5 Philippines Angina Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Philippines Angina Market Revenues & Volume Share, By Types, 2021 & 2031F |
3.7 Philippines Angina Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Philippines Angina Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of lifestyle diseases such as obesity and diabetes, leading to a higher incidence of angina. |
4.2.2 Growing awareness about cardiovascular health and early detection of heart diseases. |
4.2.3 Advancements in medical technology and treatment options for angina patients. |
4.3 Market Restraints |
4.3.1 High cost associated with angina diagnosis, treatment, and management. |
4.3.2 Limited access to healthcare facilities, especially in rural areas. |
4.3.3 Stringent regulations and lengthy approval processes for new angina treatments. |
5 Philippines Angina Market Trends |
6 Philippines Angina Market, By Types |
6.1 Philippines Angina Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Philippines Angina Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 Philippines Angina Market Revenues & Volume, By Beta Blockers, 2021- 2031F |
6.1.4 Philippines Angina Market Revenues & Volume, By Nitrates and Calcium Channel Blockers, 2021- 2031F |
6.1.5 Philippines Angina Market Revenues & Volume, By Angiotensin-Converting Enzyme Inhibitors, 2021- 2031F |
6.1.6 Philippines Angina Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Philippines Angina Market, By Types |
6.2.1 Overview and Analysis |
6.2.2 Philippines Angina Market Revenues & Volume, By Stable Angina and Unstable Angina, 2021- 2031F |
6.2.3 Philippines Angina Market Revenues & Volume, By Variant (Prinzmetal) Angina, 2021- 2031F |
6.2.4 Philippines Angina Market Revenues & Volume, By Microvascular Angina, 2021- 2031F |
6.3 Philippines Angina Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 Philippines Angina Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 Philippines Angina Market Revenues & Volume, By Cardiology Centers, 2021- 2031F |
6.3.4 Philippines Angina Market Revenues & Volume, By Others, 2021- 2031F |
7 Philippines Angina Market Import-Export Trade Statistics |
7.1 Philippines Angina Market Export to Major Countries |
7.2 Philippines Angina Market Imports from Major Countries |
8 Philippines Angina Market Key Performance Indicators |
8.1 Average wait time for angina patients to receive treatment. |
8.2 Percentage of angina patients with controlled blood pressure and cholesterol levels. |
8.3 Number of healthcare facilities offering specialized care for angina patients. |
9 Philippines Angina Market - Opportunity Assessment |
9.1 Philippines Angina Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Philippines Angina Market Opportunity Assessment, By Types, 2021 & 2031F |
9.3 Philippines Angina Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Philippines Angina Market - Competitive Landscape |
10.1 Philippines Angina Market Revenue Share, By Companies, 2024 |
10.2 Philippines Angina Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |